Find Approved Oncology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzalutamide,Androgen deprivation therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, revealed that XTANDI plus ADT reduced the risk of death by 27% compared to placebo plus ADT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lorlatinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            The drug has been recommended as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after: alectinib or ceritinib or crizotinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pralsetinib

            Therapeutic Area: Oncology Product Name: Gavreto

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Blueprint Medicines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 14, 2020

            Details:

            PANTHERx® Rare Pharmacy has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetinib), which was granted ­accelerated approval for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avelumab

            Therapeutic Area: Oncology Product Name: Bavencio

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 14, 2020

            Details:

            New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sacituzumab Govitecan

            Therapeutic Area: Oncology Product Name: Trodelvy

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $21,000.0 million Upfront Cash: $15,000.0 million

            Deal Type: Acquisition September 13, 2020

            Details:

            Acquisition provides Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate that was granted accelerated approval by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibrutinib,Rituximab

            Therapeutic Area: Oncology Product Name: Imbruvica

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            The decision follows data from the Phase III E1912 study, which shows that previously untreated adults given the drug plus rituximab lived longer without disease progression than those treated with the established chemo-immunotherapy regimen fludarabine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pralsetinib

            Therapeutic Area: Oncology Product Name: Gavreto

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 04, 2020

            Details:

            U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azacitidine

            Therapeutic Area: Oncology Product Name: Onureg

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            The approval is based on results from the pivotal Phase 3 QUAZAR® AML-001 study in which treatment with Onureg resulted in a statistically significant and clinically meaningful improvement in overall survival of nearly 10 months compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belantamab mafodotin

            Therapeutic Area: Oncology Product Name: Blenrep

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 27, 2020

            Details:

            The milestone payment is triggered after European Commission's conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enasidenib,Hydroxyurea

            Therapeutic Area: Oncology Product Name: Idhifa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            Phase 3 IDHENTIFY study evaluating IDHIFA®(enasidenib) plus best supportive care vs conventional care regimens, which include azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint.

            PharmaCompass